Pharmaceutical companies are of great interest to investors. Find out more about Novo Nordisk, a pharmaceutical leader that specializes in the treatment of diabetes.
Novo Nordisk is a leading biotechnology company that specializes in the treatment of diabetes. With more than 463 million people suffering from this disease, the Danish health company's products are indispensable. This has made it one of the largest pharmaceutical companies in the world.
For those interested in investing in this company, here is some important information about its stock profile.
Novo Nordisk was formed through the merger of Nordisk Inuslinlaboratorium and Novo Terapeutisk Laboratorium. The two companies, founded in 1923 and 1925 respectively, both develop products to help people with diabetes. Considered the best in their field, the two companies decided to join forces in 1989.
Novo Nordisk currently operates in 79 countries with more than 43,000 employees. Its products are distributed in 190 countries.
Here are some important dates in the history of Novo Nordisk since 2010 :
Like the two companies that merged to create it, Novo Nordisk specializes in the treatment of diabetes. It offers various types of drugs such as human insulin, insulin analogue, GLP-1 analogue, Gucagon and oral antidiabetic.
Novo Nordisk also deals with treatments for chronic diseases such as haemophilia and growth hormone deficiency. The group offers solutions in haematology, growth hormone, obesity and hormone therapy, among others.
Projections for diabetes predict that the number of diabetics could exceed 700 million people by 2045. Although this disease can cause serious complications such as blindness and heart attacks, 50% of sufferers remain undiagnosed. In view of these figures, this disease constitutes an inexhaustible market for pharmaceutical companies.
Novo Nordisk's expertise in the treatment of diabetes will continue to be in high demand. The two companies that have created this group have almost 100 years of experience in diabetes treatment solutions. Novo Nordisk's ambition is to produce life-saving medicines that enable all diabetics to live a better life.
Novo Nordisk also has a strong cash flow, part of which is spent on research and development. The group may also acquire other companies, with the aim of expanding its field of competence. This will consolidate its leading position in diabetes treatments.
In 2011, the Danish company was forced to pay $25 million for illegal promotion of its drug NovoSeven. In 2017, it was also ordered to pay $58.7 million regarding its diabetes drug Victoza. Problems like these hurt Novo Nordisk's brand image. In addition to causing it financial losses, a potential lawsuit may cause its prices to fall on the stock market.
